- Home
- GOSS vs ACV Comparison
GOSS vs ACV Comparison
Compare GOSS & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ACV
- Stock Information
- Founded
- GOSS 2015
- ACV 2015
- Country
- GOSS United States
- ACV United States
- Employees
- GOSS N/A
- ACV N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ACV Finance/Investors Services
- Sector
- GOSS Health Care
- ACV Finance
- Exchange
- GOSS Nasdaq
- ACV Nasdaq
- Market Cap
- GOSS 212.9M
- ACV 236.7M
- IPO Year
- GOSS 2019
- ACV N/A
- Fundamental
- Price
- GOSS $0.80
- ACV $22.14
- Analyst Decision
- GOSS Strong Buy
- ACV
- Analyst Count
- GOSS 5
- ACV 0
- Target Price
- GOSS $9.20
- ACV N/A
- AVG Volume (30 Days)
- GOSS 2.3M
- ACV 38.8K
- Earning Date
- GOSS 11-07-2024
- ACV 01-01-0001
- Dividend Yield
- GOSS N/A
- ACV 9.20%
- EPS Growth
- GOSS N/A
- ACV N/A
- EPS
- GOSS N/A
- ACV N/A
- Revenue
- GOSS $105,322,000.00
- ACV N/A
- Revenue This Year
- GOSS N/A
- ACV N/A
- Revenue Next Year
- GOSS N/A
- ACV N/A
- P/E Ratio
- GOSS N/A
- ACV N/A
- Revenue Growth
- GOSS N/A
- ACV N/A
- 52 Week Low
- GOSS $0.50
- ACV $16.82
- 52 Week High
- GOSS $1.60
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- GOSS 50.75
- ACV 44.61
- Support Level
- GOSS $0.83
- ACV $22.50
- Resistance Level
- GOSS $1.10
- ACV $23.39
- Average True Range (ATR)
- GOSS 0.08
- ACV 0.31
- MACD
- GOSS 0.02
- ACV -0.10
- Stochastic Oscillator
- GOSS 31.66
- ACV 0.79
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It seeks to achieve its investment objective by investing in a combination of convertible securities, debt and other income-producing instruments and common stocks and other equity securities.